long intergenic non-protein coding RNA 2696Genealiases: []
Q-omics provides the consensus-scored LINC02696 profile across patient tissues and cancer cell-line models. LINC02696 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, LINC02696 is differentially expressed in 15, with the highest sampling consensus in KIRC. Additionally, LINC02696 RNA expression shows 14,263 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight UVM, KIRC, and KIRP as cancer lineages where LINC02696 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02696 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02696 survival associations across molecular data types. LINC02696 RNA expression shows survival associations in the most cancer types (22). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02696 RNA expression–survival associations across cancer types. High LINC02696 expression shows unfavorable associations in READ and LIHC, but favorable associations in UVM, KIRP, UCS and PAAD. The UVM Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for LINC02696 RNA expression.
This table summarizes LINC02696 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 15. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02696. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02696 shows lower tumor expression in KIRC, LUAD, KICH, THCA, UCEC and COAD. The KIRC box plot shows higher LINC02696 RNA expression in normal versus tumor tissue (log2 FC = −0.496, t-test p < 0.001).
This table shows molecular features associated with LINC02696 in patient tissues and cancer cell lines. In patient samples, LINC02696 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set.
